

CORCEPT THERAPEUTICS INC
Form 8-K
August 12, 2005

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

August 9, 2005

Corcept Therapeutics Incorporated

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction
of incorporation)

000-50679

(Commission
File Number)

77-0487658

(I.R.S. Employer
Identification No.)

149 Commonwealth Drive, Menlo Park,
California

(Address of principal executive offices)

94025

(Zip Code)

Registrant's telephone number, including area code:

650-327-3270

275 Middlefield Rd. Suite A, Menlo Park, CA 94025

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Top of the Form

Item 2.02 Results of Operations and Financial Condition.

On August 9, 2005 Corcept Therapeutics Incorporated issued a press release announcing its financial results for the quarter ended June 30, 2005. The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(c) Exhibits.

Exhibit 99.1 Press release dated August 9, 2005

Edgar Filing: CORCEPT THERAPEUTICS INC - Form 8-K

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Corcept Therapeutics Incorporated

August 12, 2005

By: */s/ Fred Kurland*

Name: Fred Kurland

Title: Chief Financial Officer

Edgar Filing: CORCEPT THERAPEUTICS INC - Form 8-K

Top of the Form

Exhibit Index

Exhibit No.	Description
99.1	Q2 2005 Earnings Release